184 related articles for article (PubMed ID: 33051313)
1. Blood functional assay for rapid clinical interpretation of germline
Raad S; Rolain M; Coutant S; Derambure C; Lanos R; Charbonnier F; Bou J; Bouvignies E; Lienard G; Vasseur S; Farrell M; Ingster O; Baert Desurmont S; Kasper E; Bougeard G; Frébourg T; Tournier I
J Med Genet; 2021 Dec; 58(12):796-805. PubMed ID: 33051313
[TBL] [Abstract][Full Text] [Related]
2. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
3. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
7. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
[TBL] [Abstract][Full Text] [Related]
8.
Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
[TBL] [Abstract][Full Text] [Related]
9. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of low-penetrant germline TP53 D49H mutation in Japanese cancer patients.
Yamaguchi K; Urakami K; Nagashima T; Shimoda Y; Ohnami S; Ohnami S; Ohshima K; Mochizuki T; Hatakeyama K; Serizawa M; Akiyama Y; Maruyama K; Katagiri H; Ishida Y; Takahashi K; Nishimura S; Terashima M; Kawamura T; Kinugasa Y; Yamakawa Y; Onitsuka T; Ohde Y; Sugino T; Ito I; Matsubayashi H; Horiuchi Y; Mizuguchi M; Yamazaki M; Inoue K; Wakamatsu K; Sugiyama M; Uesaka K; Kusuhara M
Biomed Res; 2016; 37(4):259-64. PubMed ID: 27545002
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of novel germline TP53 variants in Swedish families.
Kharaziha P; Ceder S; Axell O; Krall M; Fotouhi O; Böhm S; Lain S; Borg Å; Larsson C; Wiman KG; Tham E; Bajalica-Lagercrantz S
Clin Genet; 2019 Sep; 96(3):216-225. PubMed ID: 31081129
[TBL] [Abstract][Full Text] [Related]
12. Somatic and Germline
Sherborne AL; Lavergne V; Yu K; Lee L; Davidson PR; Mazor T; Smirnoff IV; Horvai AE; Loh M; DuBois SG; Goldsby RE; Neglia JP; Hammond S; Robison LL; Wustrack R; Costello JF; Nakamura AO; Shannon KM; Bhatia S; Nakamura JL
Clin Cancer Res; 2017 Apr; 23(7):1852-1861. PubMed ID: 27683180
[No Abstract] [Full Text] [Related]
13. Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.
Monti P; Perfumo C; Bisio A; Ciribilli Y; Menichini P; Russo D; Umbach DM; Resnick MA; Inga A; Fronza G
Mol Cancer Res; 2011 Mar; 9(3):271-9. PubMed ID: 21343334
[TBL] [Abstract][Full Text] [Related]
14. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
Id Said B; Kim H; Tran J; Novokmet A; Malkin D
Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
[TBL] [Abstract][Full Text] [Related]
15. TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.
Qian M; Cao X; Devidas M; Yang W; Cheng C; Dai Y; Carroll A; Heerema NA; Zhang H; Moriyama T; Gastier-Foster JM; Xu H; Raetz E; Larsen E; Winick N; Bowman WP; Martin PL; Mardis ER; Fulton R; Zambetti G; Borowitz M; Wood B; Nichols KE; Carroll WL; Pui CH; Mullighan CG; Evans WE; Hunger SP; Relling MV; Loh ML; Yang JJ
J Clin Oncol; 2018 Feb; 36(6):591-599. PubMed ID: 29300620
[TBL] [Abstract][Full Text] [Related]
16. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
Rath MG; Masciari S; Gelman R; Miron A; Miron P; Foley K; Richardson AL; Krop IE; Verselis SJ; Dillon DA; Garber JE
Breast Cancer Res Treat; 2013 May; 139(1):193-8. PubMed ID: 23580068
[TBL] [Abstract][Full Text] [Related]
18. Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing.
Fortuno C; Pesaran T; Mester J; Dolinsky J; Yussuf A; McGoldrick K; James PA; Spurdle AB
Cancer Genet; 2020 Oct; 248-249():11-17. PubMed ID: 32966936
[TBL] [Abstract][Full Text] [Related]
19. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
20. Contribution of de novo and mosaic
Renaux-Petel M; Charbonnier F; Théry JC; Fermey P; Lienard G; Bou J; Coutant S; Vezain M; Kasper E; Fourneaux S; Manase S; Blanluet M; Leheup B; Mansuy L; Champigneulle J; Chappé C; Longy M; Sévenet N; Paillerets BB; Guerrini-Rousseau L; Brugières L; Caron O; Sabourin JC; Tournier I; Baert-Desurmont S; Frébourg T; Bougeard G
J Med Genet; 2018 Mar; 55(3):173-180. PubMed ID: 29070607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
